[38–41] The finding that espl1/Separase acts as an oncogene/-protein in various cancers including CML renders this protease a key target to unravel the molecular mechanisms involved in the development of centrosome amplification and clonal evolution in IM-treated CML. Here, ESPL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.